Accelitech, an innovator and developer of stereotactic radiosurgery and cancer treatment programs, declared the availability of its latest CyberKnife cancer center in Chicago, effective from the summer of 2012.
The new CyberKnife Cancer Institute of Chicago results from a dynamic collaboration between Accelitech, Swedish Covenant Hospital and well-known physicians. The new facility will offer high-tech CyberKnife treatment to Chicago patients and beyond. This innovative CyberKnife center will be the city’s first offering of its kind.
Located in the heart of the city, this new 10,000-square-foot facility will provide easy access to both downtown and suburban locations. The facility is now under construction and once the center is unveiled during this spring, the clinical team will start examining the patients for treatment.
According to the CEO of Accelitech, Kerwin Brandt, this project accentuates implementing the company’s objective to present new technology to the challenging medical scenario. The new Chicago site will complement the accelerating network of Accelitech CyberKnife centers. At present, the company has nine locations to its credit with several other initiatives on the way. These achievements demonstrate that the company is a top private developer of CyberKnife centers in U.S.A.
Based in Chicago, IL, Accelitech is an independent leading developer of stereotactic radiosurgery and cancer treatment programs. It is renowned for its broad experience and expertise operation in law, finance, healthcare, development, and clinical operations. Accelitech enables physicians and hospitals to bring new technology to market by offering the necessary grants, proficiency and legal services.